A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.
This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.
Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.
A retrospective review showed that children with FH and family history of early-onset ASCVD were more likely to have Lp(a) ≥50 mg/dL, compared with children with FH and family history of late-onset ASCVD.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Slides with take home messages of our EPCCS Practical Guidance Document, which provides practical guidance on management of persons with dyslipidaemia in primary care, with a focus on challenges faced in clinical reality.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.
AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.